Navigation Links
FDA Approves New Mechanism of Action Labeling for Ranexa(R)
Date:12/18/2007

PALO ALTO, Calif., Dec. 18 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that the U.S. Food and Drug Administration (FDA) has approved new language for the product labeling for Ranexa(R) (ranolazine extended-release tablets) which describes the ability of ranolazine to inhibit the late sodium current at therapeutic levels.

Published data on ranolazine's mechanism suggests that during ischemic episodes excess sodium can flow into cardiac cells through sodium channels. This excess sodium can trigger a subsequent overload of calcium that can lead to problems with proper contraction and relaxation of the heart. Late sodium current inhibition has been shown to improve mechanical and electrical dysfunctions of cardiac cells under these circumstances.

"We believe it is important for physicians to have as much information as possible on the mechanism of action for Ranexa and we are very pleased that the FDA has worked with us to add this new language to the approved product labeling," said Louis G. Lange, CV Therapeutics chairman and chief executive officer.

Ranexa is currently indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates. Complete product labeling is available at http://www.cvt.com.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
2. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
3. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
4. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
5. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
6. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
7. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
8. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
9. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
10. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
11. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... The participants committed to not only creating ... own time adjusting, tweaking and testing virtual models and ... for judging. , “I enjoyed being involved as a ... “The entries showed a commendable range exploring the technical ... print medium and the creativity of the contestants.” , ...
(Date:10/1/2014)... 2014 In response to its ... address sales, training and consumer engagement challenges, ... mobile applications to turn their clients’ visions into ... customized mobile app creations, are now featured on ... partnership with Toyota, StudioPMG created a robust cross-platform ...
(Date:10/1/2014)... 30, 2014 Award winning unified ... announces four new-hosted collaboration bundles that combine next ... quality conferencing experiences for low, flat rate fees. ... from, businesses have optimized solutions to meet their ... include audio only minutes (1K, 5K, 10K increments) ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 TeselaGen ... National Science Foundation to expand their bioCAD/CAM software suite, ... and modify DNA. The Small Business Innovation Research Phase ... “j5” technology under exclusive license from the Lawrence Berkeley ... BioEnergy Institute , an LBNL laboratory that develops alternative ...
Breaking Biology Technology:Array Architects Challenges Staff to Create with 3D Printer 2Digital Agency Studio PMG Launches New Case Studies on Website 2SoundConnect Launches New Audio, Web and Video Bundles 2TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3
... Metformin on Insulin Sensitization Poster Wins One ... ... Seahorse Bioscience, Inc.,leaders in real-time measurement of cellular bioenergetics announced today,the ... award at the 16th European Congress on Obesity (ECO 2008) May ...
... Include Clinical Trial Updates, BETHESDA, Md., July ... OTC Bulletin Board: NWBO), (the,"Company or NWBT"), today ... Chief Executive Officer, will deliver a presentation updating,the ... for the,treatment of cancer, at the "Next Generation ...
... ARGONNE, Ill. (July 17, 2008) Researchers at the U.S. ... industrial partners have won two R&D 100 Awards for ... scientists have been awarded 101 R&D 100 Awards since ... a prestigious R&D 100 Award -- dubbed the "Oscars ...
Cached Biology Technology:Seahorse Bioscience Receives Poster Award from the European Association for the Study of Obesity 2Northwest Biotherapeutics to Present at Next Generation Vaccine Conference 2Argonne researchers win 2 R&D 100 Awards 2Argonne researchers win 2 R&D 100 Awards 3Argonne researchers win 2 R&D 100 Awards 4
(Date:9/30/2014)... Researchers of Ludwig-Maximilians-Universitaet (LMU) in Munich report that ... cells more sensitive to chemotherapeutic drugs. They have ... a new target for anti-tumor agents. , ... Professor Stephan Sieber of the Technische Universitt Mnchen ... a potential new weapon in the fight against ...
(Date:9/30/2014)... 30, 2014  Spectra Automation, a trusted ... biotech and power generation industries, announced today ... Manager, an easy-to-use and cost-effective data collection, ... development laboratories. Most upstream ... analyzer systems. Accessing and consolidating data from ...
(Date:9/29/2014)... Clostridium ramosum , coupled with a high-fat diet, may cause ... in mBio , the online open-access journal of the ... the German Institute of Human Nutrition Potsdam-Rehbruecke in Nuthetal observed ... gained weight when fed a high-fat diet. Mice that ... even when consuming a high-fat diet, and mice that had ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2Gut bacteria promote obesity in mice 2
... Leadership Strengthened with Clinical ... Standards-Based Data Management, WHIPPANY, N.J. and ATLANTA, ... it agreed to terms to acquire Zurich,Biostatistics, Inc. ... regulatory submissions, the acquisition further strengthens,ISI,s Clinical Data ...
... SHORES, Calif., Sept. 10 ,Communication Intelligence Corporation (OTC ... signature solutions for business process,automation in the financial ... announced today the appointment of Michael Betts to,the ... over 30 years of experience in the insurance ...
... J. Michael McConnell, Director of,National Intelligence and ... Intelligence will provide valuable insights into the intelligence,challenges ... the United States,Intelligence Community 100 Day Plan for ... The Office of the Director of National Intelligence ...
Cached Biology News:Image Solutions, Inc. Acquires Zurich Biostatistics, Inc. 2Image Solutions, Inc. Acquires Zurich Biostatistics, Inc. 3Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors 2Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors 3